{"filing":{"accession_number":"0001193125-26-280223","cik":"0001534133","ticker":"CALC","company_name":"CalciMedica, Inc.","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"d40651d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1534133/000119312526280223/d40651d8k.htm"},"events":[{"id":13352,"run_id":11859,"accession_number":"0001193125-26-280223","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"CalciMedica entered into a First Amendment to its Loan and Security Agreement on June 23, 2026, materially modifying the terms of a $10,000,000 debt facility by extending the interest-only period and maturity date by one year, increasing the final payment fee by $200,000, and significantly expanding conversion rights from $1,000,000 to $3,000,000 of principal into common stock or pre-funded warrants.","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10468,"accession_number":"0001193125-26-280223","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"CalciMedica entered into a First Amendment to its existing Loan and Security Agreement on June 23, 2026, materially modifying the terms of a $10,000,000 debt facility. The amendment extends the interest-only period by one year (to September 30, 2027), extends the maturity date by one year (to September 1, 2029), increases the final payment fee by $200,000, and significantly expands conversion rights from $1,000,000 to $3,000,000 of principal into common stock or pre-funded warrants. While technically an amendment rather than a new issuance, the substantial modification of debt terms—particularly the extended maturity, increased fees, and expanded equity conversion rights—constitutes a material amendment to a direct financial obligation that would affect investor assessment of the company's capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T10:51:40.384322+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10469,"accession_number":"0001193125-26-280223","item_number":"3.02","item_title":"Unregistered Sales of Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of securities including a Conversion Option, Conversion Securities, First Amendment Warrant, and underlying common stock shares. The explicit statement that these securities \"have not been registered under the Securities Act\" and reference to incorporation of Item 1.01 details indicate a private placement or similar unregistered equity issuance, which is a classic dilutive issuance event material to investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T10:51:40.384322+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10468,"accession_number":"0001193125-26-280223","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"CalciMedica entered into a First Amendment to its existing Loan and Security Agreement on June 23, 2026, materially modifying the terms of a $10,000,000 debt facility. The amendment extends the interest-only period by one year (to September 30, 2027), extends the maturity date by one year (to September 1, 2029), increases the final payment fee by $200,000, and significantly expands conversion rights from $1,000,000 to $3,000,000 of principal into common stock or pre-funded warrants. While technically an amendment rather than a new issuance, the substantial modification of debt terms—particularly the extended maturity, increased fees, and expanded equity conversion rights—constitutes a material amendment to a direct financial obligation that would affect investor assessment of the company's capital structure and dilution risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T10:51:40.384322+00:00","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-06-24"},{"id":10469,"accession_number":"0001193125-26-280223","item_number":"3.02","item_title":"Unregistered Sales of Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of securities including a Conversion Option, Conversion Securities, First Amendment Warrant, and underlying common stock shares. The explicit statement that these securities \"have not been registered under the Securities Act\" and reference to incorporation of Item 1.01 details indicate a private placement or similar unregistered equity issuance, which is a classic dilutive issuance event material to investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T10:51:40.384322+00:00","company_name":"CalciMedica, Inc.","ticker":"CALC","filing_date":"2026-06-24"}]}